CD274 and non-small cell lung carcinoma: In patients with advanced nonsmall‐cell lung cancer (NSCLC), a number of biomarkers that can predict clinical benefit from anti‐PD‐(L)1 monotherapies have been identified,2, 6, 8, 10, 11, 12, 13, 14, 15, 16 including high tumor mutational burden (TMB), which reflects the overall neoantigen load.13